Global Benign Prostate Hyperplasia (BPH)
Treatment Market was valued at USD 1.53 billion in 2024 and is expected to
reach USD 2.51 billion by 2030 with a CAGR of 8.75% during the forecast period.
The global
benign prostate hyperplasia (BPH) treatment market is experiencing steady
growth, driven by the increasing prevalence of aging populations and rising
awareness of urological health. BPH, a non-cancerous enlargement of the
prostate gland, leads to uncomfortable urinary symptoms and significantly
impacts quality of life. As a result, demand for effective treatment
options—ranging from medication to minimally invasive procedures and surgery—is
expanding across regions. According to World Health Organization
(WHO) projections, by 2050, approximately 80% of the elderly population will
live in low- and middle-income countries. Additionally, the number of
individuals aged 80 and above is expected to triple between 2020 and 2050,
reaching nearly 426 million. Age is the leading risk factor for benign
prostatic hyperplasia (BPH), with its prevalence increasing significantly in
older men. As a result, the growing global geriatric population is likely to
drive substantial expansion in the BPH treatment market in the coming years,
with heightened demand for effective diagnosis and management solutions.
Advancements
in medical technology have introduced less invasive treatment methods with
shorter recovery times and improved outcomes, encouraging more patients to seek
timely intervention. The pharmaceutical segment remains a key part of the
market, with alpha-blockers and 5-alpha-reductase inhibitors being commonly
prescribed. Meanwhile, the rise of laser therapies and other energy-based
treatments is reshaping the surgical landscape by offering safer alternatives
with reduced side effects. Growing healthcare infrastructure in emerging
economies is also fostering access to diagnosis and treatment, further
propelling market growth. The lifestyle changes, increased healthcare
expenditure, and ongoing research and development in urology are contributing
to the evolution of BPH management. With a focus on improving patient comfort
and long-term results, the global BPH treatment market is poised to continue
expanding as both awareness and technological innovation advance.
Key Market Drivers
Aging Population
The aging population is one of the most
significant and influential drivers of the global benign prostate hyperplasia
(BPH) treatment market. For instance, according to WHO 2025, global life expectancy at birth
reached 73.3 years in 2024, rising by 8.4 years since 1995. The population aged
60 and older is expected to grow from 1.1 billion in 2023 to 1.4 billion by
2030, with the trend accelerating notably in developing regions. As
men age, the likelihood of developing BPH increases substantially, making age a
primary risk factor for the condition. BPH is characterized by the
non-cancerous enlargement of the prostate gland, which commonly affects men
over the age of 50. This physiological change occurs due to hormonal
fluctuations, particularly the imbalance between testosterone and
dihydrotestosterone (DHT), which promotes prostate cell growth. Over time, this
leads to the gradual thickening and growth of the prostate, often resulting in
urinary symptoms such as increased frequency, urgency, and incomplete bladder
emptying.
Globally, improvements in healthcare,
nutrition, and living standards have significantly extended life expectancy.
This demographic shift means a larger proportion of the population is entering
age brackets where BPH is more prevalent. Consequently, the demand for
diagnostic, pharmaceutical, and surgical interventions is increasing.
Healthcare systems, especially in developed countries, are seeing a growing
burden of age-related conditions, with BPH being a leading urological issue
among elderly men.
As people live longer and prioritize
quality of life in older age, there is greater willingness to seek treatment
for chronic but manageable conditions like BPH. The aging population is also
more likely to be covered by healthcare insurance or public health systems,
which further facilitates access to treatment. In emerging economies,
increasing awareness among the elderly and improvements in medical
infrastructure are similarly boosting diagnosis and treatment rates.
As this demographic trend continues, it
is expected that the prevalence of BPH will rise, placing sustained demand on
healthcare providers and driving innovation in less invasive, more effective
treatment solutions. In this context, the aging population not only fuels
market growth but also shapes the evolution of therapeutic strategies and
healthcare delivery models for BPH.
Increasing Awareness and Diagnosis
Increasing awareness and diagnosis of
benign prostate hyperplasia (BPH) is playing a crucial role in driving the
growth of the global BPH treatment market. In the past, many men hesitated to
seek medical help for urinary symptoms due to embarrassment, lack of knowledge,
or the misconception that such symptoms were simply a normal part of aging.
However, growing public health campaigns, educational initiatives, and the
proactive efforts of healthcare professionals have begun to change this
narrative. Men are now becoming more informed about the importance of early
detection and treatment of prostate conditions, including BPH. Acording to
the Global Cancer Observatory’s GLOBOCAN 2022 report, prostate cancer ranked
4th among all cancer types, with approximately 1.47 million new cases reported
in 2022. This high incidence rate significantly increases the demand for
effective treatment options, driving the growth of the prostate cancer
therapeutics market. Also, November is globally
recognized as Prostate Cancer Awareness Month, focusing on raising awareness
for prostate cancer in men. In November 2024, Europa Uomo members in Hungary
and Italy contributed to this cause by launching prostate cancer testing programs
as part of the "Movember" campaign
Healthcare providers and organizations
are promoting routine screenings, particularly for men over the age of 50,
which has led to earlier identification of BPH symptoms. The widespread
availability of non-invasive diagnostic tools, such as prostate-specific
antigen (PSA) tests and ultrasound, has further facilitated timely diagnosis.
This shift towards earlier and more frequent screening enables physicians to
manage the condition before complications arise, often using medications or
minimally invasive therapies rather than surgery.
Digital health platforms, telemedicine,
and online resources are also playing a significant role in raising awareness.
Men are increasingly researching symptoms online and engaging in virtual
consultations, leading to greater recognition of BPH and its impact on quality
of life. In emerging markets, increased access to healthcare services, growing
urbanization, and targeted awareness campaigns are helping reduce stigma and
misinformation surrounding prostate health.
As awareness spreads and diagnostic
capabilities improve, more men are entering the treatment pathway at earlier
stages of the disease. This trend not only drives demand for BPH treatments but
also encourages the development of innovative therapies tailored for early and
moderate cases. Ultimately, the growing emphasis on awareness and diagnosis is
transforming BPH from a neglected condition into a manageable aspect of men’s
health, expanding the market significantly.
Technological Advancements
Technological advancements are
significantly shaping the global benign prostate hyperplasia (BPH) treatment
market by offering safer, more effective, and patient-friendly treatment
options. Traditional surgical methods, such as transurethral resection of the
prostate (TURP), while effective, often involve longer hospital stays,
increased risk of complications, and extended recovery periods. In contrast,
modern technologies are enabling minimally invasive procedures that reduce
pain, shorten downtime, and improve clinical outcomes, thereby enhancing
patient acceptance and satisfaction.
Innovations such as laser therapies
(e.g., HoLEP and GreenLight laser), prostatic urethral lift systems, water
vapor therapy (Rezūm), and robotic-assisted surgeries have revolutionized BPH
treatment. These procedures are designed to precisely target and remove excess
prostate tissue with minimal damage to surrounding areas. As a result, patients
experience fewer side effects, including reduced risk of incontinence and
sexual dysfunction—common concerns with traditional surgery. These improvements
make advanced technologies particularly appealing to younger and more active
patients who demand faster recovery and minimal lifestyle disruption.
In addition, advances in diagnostic
technologies such as high-resolution imaging, urodynamic studies, and real-time
guidance systems enable more accurate assessments of prostate size and urinary
function, allowing for better treatment planning. The integration of digital
tools and artificial intelligence in urology is also paving the way for
personalized treatment strategies and improved monitoring of patient outcomes.
As the global healthcare industry
increasingly focuses on value-based care, providers are adopting technologies
that offer long-term efficacy and cost efficiency. As medical device
manufacturers continue to innovate, competition in the BPH market is
intensifying, driving further improvements and affordability. These
advancements not only expand the range of treatment options but also improve
accessibility, especially in outpatient and ambulatory care settings.
Consequently, technological progress is a central force propelling the BPH
treatment market forward, meeting both clinical and patient expectations.
Download Free Sample Report
Key Market Challenges
High Cost of Advanced Treatments
The high cost of advanced treatments
poses a significant challenge to the growth and accessibility of the global
benign prostate hyperplasia (BPH) treatment market. As medical technology
evolves, newer treatment modalities such as laser therapies (e.g., HoLEP,
GreenLight), water vapor therapy (Rezūm), and prostatic urethral lift (UroLift)
have emerged as preferred options due to their minimally invasive nature,
shorter recovery times, and reduced side effects. However, these benefits come
at a considerable financial cost. The equipment required for these procedures
is often expensive, and so are the associated operational and maintenance
costs, which are ultimately passed on to the patients or healthcare systems.
In many countries, especially those with
limited healthcare funding or weak insurance infrastructure, the affordability
of such advanced treatments becomes a major barrier. Patients in low- and
middle-income regions may be forced to rely on older, more invasive procedures
or pharmacological therapies, even when newer options would offer better
outcomes. The private healthcare settings tend to dominate the availability of
these innovations, making them inaccessible to individuals relying on public
health services.
This economic disparity not only limits
patient access but also discourages widespread adoption by healthcare providers
due to the high initial investment. In addition, inconsistent or inadequate
reimbursement policies in many regions further restrict the uptake of newer
treatment modalities, particularly in outpatient settings. Without broader
financial support or cost reduction strategies, the high cost of advanced BPH
treatments remains a key obstacle to ensuring equitable access and scaling the
market globally.
Competition from Alternative Therapies
Competition from alternative therapies
presents a notable challenge to the global benign prostate hyperplasia (BPH)
treatment market. In many regions, especially in Asia, Africa, and parts of
Latin America, patients often turn to herbal remedies, traditional medicine, or
dietary supplements as initial approaches to managing BPH symptoms. These
alternative therapies are widely accessible, culturally accepted, and perceived
to have fewer side effects compared to conventional pharmaceutical or surgical
treatments. As a result, a significant portion of the target population delays
seeking clinically approved medical interventions, which can lead to disease
progression and reduced effectiveness of later-stage treatments.
The global market is saturated with
over-the-counter supplements claiming to support prostate health. Products
containing ingredients like saw palmetto, pygeum, and beta-sitosterol are
commonly marketed as natural remedies for urinary issues associated with BPH.
Although some users report symptomatic relief, these supplements typically lack
robust clinical evidence and standardization, making their efficacy variable
and unpredictable. Still, their affordability and ease of access make them
attractive, especially for individuals with mild symptoms or limited healthcare
access.
The prevalence of these alternative
options also creates a competitive environment for pharmaceutical companies and
healthcare providers. Convincing patients to transition from traditional or
unverified remedies to clinically validated treatments often requires
substantial awareness efforts and physician engagement. This dynamic adds
complexity to patient management and slows down the adoption of modern
therapies. Unless addressed through education, regulation, and improved
healthcare access, the preference for alternative treatments will continue to
challenge the growth and reach of the BPH treatment market.
Key Market Trends
Shift Toward Minimally Invasive Procedure
The shift toward minimally
invasive procedures is one of the most prominent trends shaping the global
benign prostate hyperplasia (BPH) treatment market. Traditionally, BPH
treatment involved surgical interventions such as transurethral resection of
the prostate (TURP), which, while effective, often required prolonged hospital
stays, significant recovery time, and a higher risk of complications such as
bleeding and sexual dysfunction. In contrast, minimally invasive procedures
offer a less traumatic alternative with quicker recovery, fewer complications,
and a reduced risk of side effects, making them increasingly popular among both
patients and healthcare providers.
Technologies like laser
therapy (e.g., Holmium Laser Enucleation of the Prostate, HoLEP), prostatic
urethral lift (UroLift), and water vapor therapy (Rezūm) have gained traction
due to their ability to treat BPH with precision and efficiency. These treatments
are performed using advanced instruments that can target the enlarged prostate
tissue without the need for large incisions, leading to shorter hospital stays,
faster recovery times, and less post-operative pain. As a result, many patients
are opting for these procedures over traditional surgery, valuing the minimal
downtime and reduced risks.
This shift also aligns with a
broader trend in healthcare toward procedures that maximize patient comfort and
minimize disruption to daily life. The growing popularity of minimally invasive
treatments is driving innovation in the field, encouraging the development of
more effective, less invasive therapies. As awareness of these alternatives
spreads, the market for minimally invasive BPH treatments is expected to
expand, offering more choices for patients and enhancing the overall treatment
landscape.
Expansion in Emerging Markets
The expansion of the benign prostatic
hyperplasia (BPH) treatment market in emerging economies is a significant
trend, driven by several key factors. Rapid urbanization and the growth of the
middle class in regions such as Asia, Latin America, and parts of Africa are
increasing the demand for healthcare services, including BPH treatments. This
demographic shift is accompanied by an aging population, leading to a higher
prevalence of BPH and a corresponding need for effective treatment options. Improved
healthcare infrastructure in these regions is facilitating better access to
medical services, enabling more patients to seek timely diagnosis and treatment
for BPH. The greater awareness of prostate health is encouraging men to seek
medical attention for urinary symptoms, which were previously underreported due
to cultural stigmas.
The availability of cost-effective
treatment options is also contributing to market growth. Minimally invasive
procedures, such as laser therapies and prostatic urethral lift (UroLift),
offer effective solutions with shorter recovery times and fewer complications,
making them attractive alternatives to traditional surgical methods. These
advancements are particularly appealing in emerging markets, where healthcare
resources may be limited, and there is a strong emphasis on cost-effective
care. The favorable reimbursement policies and increased investment in
healthcare by both public and private sectors are supporting the adoption of
advanced BPH treatments. As a result, the BPH treatment market in emerging
economies is poised for significant growth, offering opportunities for both
local and international healthcare providers to expand their presence and meet
the rising demand for quality care.
Segmental Insights
Drug Treatment Insights
Based on drug treatment, alpha
blockers emerge as the Fastest Growing Segment in the benign prostatic hyperplasia (BPH) treatment
market. These medications, including tamsulosin and alfuzosin, are the
first-line treatment due to their rapid onset of action and effectiveness in
relieving urinary symptoms. Alpha blockers work by relaxing the smooth muscles
of the prostate and bladder neck, which improves urine flow and reduces
BPH-related symptoms such as frequent urination and urgency.
5-alpha reductase inhibitors, such as finasteride
and dutasteride, are often used for long-term management, particularly in
patients with larger prostate sizes. However, they work more slowly, taking
several months to show full benefits, and they are associated with side effects
such as decreased libido or erectile dysfunction, which can limit patient
adherence. Phosphodiesterase-5 inhibitors, like tadalafil, are less commonly
used and are typically prescribed for men who also have erectile dysfunction.
While they can improve urinary symptoms, they are not as widely adopted as
alpha blockers.
Surgical
Treatment Insights
Based on surgical treatment, Transurethral
Resection of the Prostate (TURP) remains the dominant procedure. TURP has long
been considered the gold standard for surgical BPH treatment due to its proven
effectiveness in relieving urinary symptoms. The procedure involves removing
excess prostate tissue through the urethra, which improves urine flow and
reduces symptoms significantly. TURP is widely accepted due to its long track
record, reliable outcomes, and relatively low complication rates, making it the
first choice for many urologists. While newer techniques such as Prostatic
Urethral Lift (PUL), laser surgeries, and Transurethral Microwave Therapy
(TUMT) are gaining popularity due to their minimally invasive nature and
shorter recovery times, they are still not as widely used as TURP. These newer
options often have more specific indications, and in some cases, their
long-term effectiveness is still being studied. As a result, TURP continues to
dominate as the preferred surgical option for BPH.
Download Free Sample Report
Regional Insights
North America dominated the global Benign Prostate
Hyperplasia (BPH) treatment market due to several key factors. First, the
region has a large aging population, with a higher incidence of BPH, driving
the demand for effective treatments. In addition, advanced healthcare
infrastructure, including state-of-the-art medical facilities and skilled
urologists, ensures that patients have access to a wide range of treatment
options, from medications to minimally invasive surgeries. North America
benefits from high healthcare spending, which supports the availability and
adoption of the latest treatment technologies, such as laser therapies,
prostatic urethral lift (UroLift), and new pharmaceutical innovations. The
presence of major pharmaceutical companies and medical device manufacturers
also fosters a competitive environment, driving the development and
commercialization of advanced treatments.The robust reimbursement policies and
patient awareness programs in the U.S. and Canada contribute to widespread
access to quality care, further solidifying North America’s dominant market
position.
Recent Developments
- In October 2024, Boston
Scientific Corporation, a leading U.S.-based medical technology company,
inaugurated its new manufacturing site in China in October 2024. The facility
features advanced workshops and warehouse spaces designed to meet both global
and Chinese standards. This strategic move aims to enhance the company’s
production capabilities and supply chain efficiency in the Asia-Pacific region.
By establishing a local presence in China, Boston Scientific strengthens its
market position and ensures faster delivery of medical devices, including
treatments for benign prostatic hyperplasia (BPH), while aligning with the
region’s regulatory and quality compliance requirements.
- In April 2024, Teleflex Incorporated, a
U.S.-based medical technology firm, officially launched the UroLift® 2 System,
an updated version of its widely used treatment for benign prostatic
hyperplasia (BPH). The new system features advanced Tissue Control technology,
designed to enhance procedural precision and outcomes. The UroLift 2 System is
intended to provide a minimally invasive alternative to traditional BPH
surgeries, offering quicker recovery times and improved symptom relief. With
this launch, Teleflex aims to further solidify its leadership in the BPH
treatment market by offering more refined and effective solutions for patients
and healthcare providers.
- In August 2024, PROCEPT BioRobotics
Corporation, based in the U.S., received FDA clearance for its HYDROS Robotic
System, designed for the treatment of benign prostatic hyperplasia (BPH). This
approval marks a significant milestone for the company as it expands its
portfolio of robotic-assisted surgical systems. The HYDROS system aims to offer
enhanced precision and improved patient outcomes through minimally invasive
techniques. With FDA clearance, PROCEPT BioRobotics can now introduce its
next-generation technology to the U.S. market, reinforcing its commitment to
innovation in urologic care and strengthening its competitive position in the
BPH treatment landscape.
- In July 2023, Italian pharmaceutical
company Recordati and UK-based GlaxoSmithKline (GSK) announced a strategic
partnership to commercialize the BPH medications Avodart and Combodart/Duodart
in 21 countries across Europe. The agreement excludes only those territories
where GSK already holds an existing distribution arrangement. This
collaboration leverages Recordati’s strong commercial infrastructure and GSK’s
established product portfolio to expand patient access to these key BPH
therapies. The partnership is expected to enhance market penetration, support
regional treatment accessibility, and drive growth for both companies in the
European pharmaceutical market focused on men’s health and urological
conditions.
Key Market Players
- Boston Scientific Corporation
- Coloplast Corporation
- Teleflex Incorporated
- Olympus Corporation
- Glaxo Smith Kline PLC
- Eli Lily
- Abott Laboratories
- Medifocus Inc.
- Urologix, LLC
- Pfizer Inc
|
By Drug Treatment
|
By Surgical Treatment
|
By End User
|
By Region
|
- Alpha Blockers
- 5-Alpha Reductase
Inhibitors
- phosphodiesterase-5
inhibitors
|
- Transurethral resection of
the prostate (TURP)
- Prostatic Urethral Lift
(PUL)
- Prostatectomy
- Laser Surgery
- Transurethral Microwave
Technique (TUMT)
- Transurethral Needle
Ablation of the Prostate (TUNA)
- Others
|
- Hospitals & Clinics
- Ambulatory Surgical
Centers
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Benign Prostate Hyperplasia
(BPH) Treatment Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Benign Prostate Hyperplasia (BPH)
Treatment Market, By Drug
Treatment:
o
Alpha Blockers
o
5-Alpha Reductase Inhibitors
o phosphodiesterase-5 inhibitors
- Benign Prostate Hyperplasia (BPH)
Treatment Market, By Surgical Treatment:
o
Transurethral resection of the prostate
(TURP)
o
Prostatic Urethral Lift (PUL)
o
Prostatectomy
o
Laser Surgery
o
Transurethral Microwave Technique (TUMT)
o
Transurethral Needle Ablation of the
Prostate (TUNA)
o
Others
- Benign Prostate Hyperplasia (BPH)
Treatment Market, By End
User:
o
Hospitals & Clinics
o
Ambulatory Surgical Centers
o
Others
- Benign Prostate Hyperplasia (BPH)
Treatment Market, By Region:
o North
America
§ United
States
§ Canada
§ Mexico
o Europe
§ France
§ United
Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South
Korea
o South
America
§ Brazil
§ Argentina
§ Colombia
o Middle
East & Africa
§ South
Africa
§ Saudi
Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major
companies present in the Global Benign
Prostate Hyperplasia (BPH) Treatment Market.
Available Customizations:
Global Benign Prostate Hyperplasia (BPH) Treatment Market
report with the given market data, TechSci Research, offers customizations
according to a company's specific needs. The following customization options
are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
Global Benign Prostate Hyperplasia (BPH) Treatment Market
is an upcoming report to be released soon. If you wish an early delivery of
this report or want to confirm the date of release, please contact us at [email protected]